Study Evaluating TTI-237 in Advanced Malignant Solid Tumors.

Stopped early · Phase 1

Conditions studied: Tumors, Neoplasms

In brief

The purpose of this study is to evaluate the safety, tolerability, and MTD (maximum tolerated dose) of TTI-237 for the treatment of subjects with advanced malignant solid tumors.

Key facts

Study ID

NCT00195325

Run by

Wyeth is now a wholly owned subsidiary of Pfizer

People needed

45

Starts

2005-08-01

Last updated by the study team

2007-03-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented diagnosis of malignant solid tumor with measurable disease
• Life expectancy of at least 12 weeks
• ECOG (The Eastern Cooperative Oncology Group scale) performance status of 0, 1, or 2

You may not qualify if…

• Recent major surgery, radiation therapy or anti-cancer treatment
• History of any other prior malignancy within the last 5 years

Where it is running

• Study site — Lexington, Kentucky, United States
• Study site — Cleveland, Ohio, United States
• Study site — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.